Pharmaceuticals - Community Register


Community register of medicinal products for human use


Product information

Invented name: Amyvid   
Auth. number : EU/1/12/805
Active substance : Florbetapir (18F)
ATC: Anatomical main group: V - Various
Therapeutic subgroup: V09 - Diagnostic radiopharmaceuticals
Pharmacological subgroup: V09A - Central nervous system
Chemical subgroup: V09AX - Other central nervous system diagnostic radiopharmaceuticals
Chemical substance: V09AX05 - Florbetapir (18F)
(See WHO ATC Index)
Indication: This medicinal product is for diagnostic use only.
Amyvid is a radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of β amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment. Amyvid should be used in conjunction with a clinical evaluation.
A negative scan indicates sparse or no plaques, which is not consistent with a diagnosis of AD. For the limitations in the interpretation of a positive scan, see sections 4.4 and 5.1. of the Product Information.
Marketing Authorisation Holder: Eli Lilly Nederland B.V.
Grootslag 1-5, NL-3991 RA Houten, Nederland
EPAR and active package presentations

Package presentations

Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
17/01/2013 Centralised - Authorisation EMEA/H/C/2422 (2013)137 of 14/01/2013
08/04/2013 Centralised - Notification EMEA/H/C/2422/N/1
Updated with Decision(2014)4510 of 27/06/2014
25/07/2013 Centralised - Variation EMEA/H/C/2422/II/2
Updated with Decision(2014)4510 of 27/06/2014
18/10/2013 Centralised - Variation EMEA/H/C/2422/IB/5/G
Updated with Decision(2014)4510 of 27/06/2014
18/10/2013 Centralised - Variation EMEA/H/C/2422/IB/4/G
Updated with Decision(2014)4510 of 27/06/2014
18/10/2013 Centralised - Variation EMEA/H/C/2422/IB/6/G
Updated with Decision(2014)4510 of 27/06/2014
01/07/2014 Centralised - Yearly update (2014)4510 of 27/06/2014
22/12/2014 Centralised - Variation EMEA/H/C/2422/IB/12/G